INT2/HSTI Coamplification in Breast Cancer
Author Information
Author(s): A. Borg, H. Sigurdsson, G.M. Clark, M. Fernö, S.A.W. Fuqua, H. Olsson, D. Killander, W.L. McGuire
Primary Institution: Department of Oncology, University Hospital, Lund, Sweden; Department of Oncology/Medicine, University of Texas Health Science Center at San Antonio, USA
Hypothesis
Does coamplification of INT2 and HSTI genes in primary breast cancer correlate with hormone-dependent phenotype and prognosis?
Conclusion
Coamplification of INT2 and HSTI genes is associated with a hormone-dependent phenotype and poorer disease-free survival in breast cancer patients.
Supporting Evidence
- 27 out of 311 tumors showed INT2/HSTI amplification.
- 96% of amplified tumors were estrogen receptor positive.
- Patients with amplified tumors had shorter disease-free survival compared to those without amplification.
Takeaway
Some breast cancer tumors have extra copies of certain genes, which can make them more aggressive and harder to treat.
Methodology
The study analyzed 311 invasive breast cancer tumors for INT2/HSTI gene amplification using slot blot and Southern blot techniques.
Potential Biases
Potential bias due to variations in treatment received by patients.
Limitations
The study's findings may not apply to all breast cancer patients, especially those with advanced disease.
Participant Demographics
Patients were from southern Sweden, aged 31-92 years, with 22% premenopausal and 78% postmenopausal.
Statistical Information
P-Value
0.001
Confidence Interval
95% confidence interval 1.3-12
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website